243 related articles for article (PubMed ID: 22407818)
1. Aromatase inhibitor treatment of breast cancer cells increases the expression of let-7f, a microRNA targeting CYP19A1.
Shibahara Y; Miki Y; Onodera Y; Hata S; Chan MS; Yiu CC; Loo TY; Nakamura Y; Akahira J; Ishida T; Abe K; Hirakawa H; Chow LW; Suzuki T; Ouchi N; Sasano H
J Pathol; 2012 Jul; 227(3):357-66. PubMed ID: 22407818
[TBL] [Abstract][Full Text] [Related]
2. MicroRNA-125b upregulation confers aromatase inhibitor resistance and is a novel marker of poor prognosis in breast cancer.
Vilquin P; Donini CF; Villedieu M; Grisard E; Corbo L; Bachelot T; Vendrell JA; Cohen PA
Breast Cancer Res; 2015 Jan; 17(1):13. PubMed ID: 25633049
[TBL] [Abstract][Full Text] [Related]
3. Aromatase inhibitor regulates let-7 expression and let-7f-induced cell migration in endometrial cells from women with endometriosis.
Cho S; Mutlu L; Zhou Y; Taylor HS
Fertil Steril; 2016 Sep; 106(3):673-80. PubMed ID: 27320036
[TBL] [Abstract][Full Text] [Related]
4. Decrease of let-7f in low-dose metronomic Paclitaxel chemotherapy contributed to upregulation of thrombospondin-1 in breast cancer.
Tao WY; Liang XS; Liu Y; Wang CY; Pang D
Int J Biol Sci; 2015; 11(1):48-58. PubMed ID: 25552929
[TBL] [Abstract][Full Text] [Related]
5. The role of microRNA-128a in regulating TGFbeta signaling in letrozole-resistant breast cancer cells.
Masri S; Liu Z; Phung S; Wang E; Yuan YC; Chen S
Breast Cancer Res Treat; 2010 Nov; 124(1):89-99. PubMed ID: 20054641
[TBL] [Abstract][Full Text] [Related]
6. Accurate Prediction and Validation of Response to Endocrine Therapy in Breast Cancer.
Turnbull AK; Arthur LM; Renshaw L; Larionov AA; Kay C; Dunbier AK; Thomas JS; Dowsett M; Sims AH; Dixon JM
J Clin Oncol; 2015 Jul; 33(20):2270-8. PubMed ID: 26033813
[TBL] [Abstract][Full Text] [Related]
7. MicroRNA let-7f inhibits tumor invasion and metastasis by targeting MYH9 in human gastric cancer.
Liang S; He L; Zhao X; Miao Y; Gu Y; Guo C; Xue Z; Dou W; Hu F; Wu K; Nie Y; Fan D
PLoS One; 2011 Apr; 6(4):e18409. PubMed ID: 21533124
[TBL] [Abstract][Full Text] [Related]
8. Molecular characterization of aromatase inhibitor-resistant, tamoxifen-resistant and LTEDaro cell lines.
Masri S; Phung S; Wang X; Chen S
J Steroid Biochem Mol Biol; 2010 Feb; 118(4-5):277-82. PubMed ID: 19897035
[TBL] [Abstract][Full Text] [Related]
9. Changes in expression of oestrogen regulated and proliferation genes with neoadjuvant treatment highlight heterogeneity of clinical resistance to the aromatase inhibitor, letrozole.
Miller WR; Larionov A
Breast Cancer Res; 2010; 12(4):R52. PubMed ID: 20646288
[TBL] [Abstract][Full Text] [Related]
10. MicroRNA let-7a suppresses breast cancer cell migration and invasion through downregulation of C-C chemokine receptor type 7.
Kim SJ; Shin JY; Lee KD; Bae YK; Sung KW; Nam SJ; Chun KH
Breast Cancer Res; 2012 Jan; 14(1):R14. PubMed ID: 22251626
[TBL] [Abstract][Full Text] [Related]
11. Efficacy and mechanism of action of Proellex, an antiprogestin in aromatase overexpressing and Letrozole resistant T47D breast cancer cells.
Gupta A; Mehta R; Alimirah F; Peng X; Murillo G; Wiehle R; Mehta RG
J Steroid Biochem Mol Biol; 2013 Jan; 133():30-42. PubMed ID: 22939887
[TBL] [Abstract][Full Text] [Related]
12. A Her2-let-7-β2-AR circuit affects prognosis in patients with Her2-positive breast cancer.
Liu D; Deng Q; Sun L; Wang T; Yang Z; Chen H; Guo L; Liu Y; Ma Y; Guo N; Shi M
BMC Cancer; 2015 Nov; 15():832. PubMed ID: 26526356
[TBL] [Abstract][Full Text] [Related]
13. Let-7b inhibits human cancer phenotype by targeting cytochrome P450 epoxygenase 2J2.
Chen F; Chen C; Yang S; Gong W; Wang Y; Cianflone K; Tang J; Wang DW
PLoS One; 2012; 7(6):e39197. PubMed ID: 22761738
[TBL] [Abstract][Full Text] [Related]
14. The effects of Nobiletin, Hesperetin, and Letrozole in a combination on the activity and expression of aromatase in breast cancer cells.
Rahideh ST; Keramatipour M; Nourbakhsh M; Koohdani F; Hoseini M; Shidfar F
Cell Mol Biol (Noisy-le-grand); 2017 Feb; 63(2):9-13. PubMed ID: 28364779
[TBL] [Abstract][Full Text] [Related]
15. New cell culture model for aromatase inhibitor-resistant breast cancer shows sensitivity to fulvestrant treatment and cross-resistance between letrozole and exemestane.
Hole S; Pedersen AM; Hansen SK; Lundqvist J; Yde CW; Lykkesfeldt AE
Int J Oncol; 2015 Apr; 46(4):1481-90. PubMed ID: 25625755
[TBL] [Abstract][Full Text] [Related]
16. Aromatase inhibitors for treatment of advanced breast cancer in postmenopausal women.
Gibson LJ; Dawson C; Lawrence DH; Bliss JM
Cochrane Database Syst Rev; 2007 Jan; (1):CD003370. PubMed ID: 17253488
[TBL] [Abstract][Full Text] [Related]
17. HIF-1α stimulates aromatase expression driven by prostaglandin E2 in breast adipose stroma.
Samarajeewa NU; Yang F; Docanto MM; Sakurai M; McNamara KM; Sasano H; Fox SB; Simpson ER; Brown KA
Breast Cancer Res; 2013 Apr; 15(2):R30. PubMed ID: 23566437
[TBL] [Abstract][Full Text] [Related]
18. Hormonal therapies for early breast cancer: systematic review and economic evaluation.
Hind D; Ward S; De Nigris E; Simpson E; Carroll C; Wyld L
Health Technol Assess; 2007 Jul; 11(26):iii-iv, ix-xi, 1-134. PubMed ID: 17610808
[TBL] [Abstract][Full Text] [Related]
19. Induction of aromatase (CYP19) expression in breast cancer cells through a nongenomic action of estrogen receptor alpha.
Kinoshita Y; Chen S
Cancer Res; 2003 Jul; 63(13):3546-55. PubMed ID: 12839940
[TBL] [Abstract][Full Text] [Related]
20. The HDAC inhibitor LBH589 (panobinostat) is an inhibitory modulator of aromatase gene expression.
Chen S; Ye J; Kijima I; Evans D
Proc Natl Acad Sci U S A; 2010 Jun; 107(24):11032-7. PubMed ID: 20534486
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
